Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols

Paul Z. Chen[1], Niklas Bobrovitz[2-4], Zahra Premji[5], Marion Koopmans[6], David N. Fisman[7,8], Frank X. Gu[1,9]*

Affiliations:

[1]Department of Chemical Engineering & Applied Chemistry, University of Toronto, Toronto, Canada

[2]Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

[3]Department of Critical Care Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

[4]O'Brien Institute of Public Health, University of Calgary, Calgary, Canada

[5]Libraries & Cultural Resources, University of Calgary, Calgary, Canada

[6]Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands

[7]Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

[8]Division of Infectious Diseases, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

[9]Institute of Biomedical Engineering, University of Toronto, Toronto, Canada

*Correspondence to: f.gu@utoronto.ca

Abstract

Understanding the factors that mediate overdispersion in SARS-CoV-2 transmissibility is crucial towards mitigating the COVID-19 pandemic. Using a systematically developed dataset, we meta-analyze respiratory viral loads (rVLs) of SARS-CoV-2, SARS-CoV-1 and influenza A(H1N1)pdm09 from 15 countries and model infectiousness by shedding viable virus via droplets and aerosols. Our results indicate heterogeneity in rVL as an intrinsic virological factor facilitating greater overdispersion in the COVID-19 pandemic than in the 2009 H1N1 pandemic. For COVID-19, case heterogeneity remains broad throughout the infectious period, including for pediatric and asymptomatic infections. Many cases inherently present minimal transmission risk, whereas highly infectious individuals shed tens to thousands of SARS-CoV-2 virions/min via droplets and aerosols while breathing, talking and singing. Coughing increases the contagiousness, especially in close contact, of symptomatic cases relative to asymptomatic ones. Our findings show how individual case variations influence SARS-CoV-2 transmissibility and present considerations for disease control.

One Sentence Summary: Intrinsic case variation in respiratory viral load facilitates broad overdispersion in SARS-CoV-2 transmissibility.

37 **Main Text**

38 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing
39 the coronavirus disease 2019 (COVID-19) pandemic with more than 50.9 million infections and
40 1.2 million deaths (as of 10 November 2020) (*1*). For respiratory virus transmission, airway
41 epithelial cells shed virions to the extracellular fluid before atomization (from breathing, talking,
42 singing, coughing and aerosol-generating procedures) partitions them into a polydisperse mixture
43 of particles that are expelled to the ambient environment. Aerosols (≤100 μm) can be inhaled
44 nasally, whereas droplets (>100 μm) tend to be excluded (*2, 3*). For direct transmission, droplets
45 must be sprayed ballistically onto susceptible tissue (*4*). Hence, droplets predominantly deposit
46 on nearby surfaces, potentiating indirect transmission. Aerosols can be further categorized based
47 on typical travel characteristics: short-range aerosols (50-100 μm) tend to settle within 2 m; long-
48 range ones (10-50 μm) often travel beyond 2 m based on emission force; and buoyant aerosols
49 (≤10 μm) remain suspended and travel based on airflow profiles for minutes to many hours (*4,*
50 *5*). Although proximity has been associated with infection risk for COVID-19 (*6*), studies have
51 also suggested that long-range airborne transmission occurs conditionally (*7-9*).

52 While the basic reproductive number has been estimated to be 2.0-3.6 (*10, 11*),
53 transmissibility of SARS-CoV-2 is highly overdispersed (dispersion parameter *k*, 0.10-0.58),
54 with numerous instances of superspreading (*7-9*) and few cases (10-20%) causing many
55 secondary infections (80%) (*12-14*). Similarly, few cases drive the transmission of SARS-CoV-1
56 (*k*, 0.16-0.17) (*15*), whereas influenza A(H1N1)pdm09 transmits more homogeneously (*k*, 7.4-
57 14.4) (*16, 17*), despite both viruses spreading by contact, droplets and aerosols (*18, 19*).
58 Although understanding the determinants of overdispersion is crucial towards characterizing
59 transmissibility and developing effective strategies to limit infection (*20*), mechanistic

60 associations for *k* remain unclear. As an empirical estimate, *k* depends on myriad extrinsic
61 (behavioral, environmental and invention) and host factors. Nonetheless, *k* remains similar across
62 distinct outbreaks of a virus (*15*), suggesting that intrinsic virological factors mediate
63 overdispersion for emerging infections.

64 Here, we investigated how intrinsic case variation in rVL facilitates overdispersion in
65 SARS-CoV-2 transmissibility. By systematic review, we developed a comprehensive dataset of
66 rVLs from cases of COVID-19, SARS and A(H1N1)pdm09. Using comparative meta-analyses,
67 we found that heterogeneity in rVL was associated with overdispersion among these emerging
68 infections. To assess potential sources of case heterogeneity, we analyzed SARS-CoV-2 rVLs
69 across age and symptomatology subgroups as well as disease course. To interpret the influence
70 of heterogeneity in rVL on individual infectiousness, we modelled likelihoods of shedding viable
71 virus via respiratory droplets and aerosols.
72

73 **Systematic review**

74 We conducted a systematic review on virus quantitation in respiratory specimens taken during
75 the infectious periods of SARS-CoV-2 (-3 to 10 days from symptom onset [DFSO]) (*21-23*),
76 SARS-CoV-1 (0-20 DFSO) (*24*) and A(H1N1)pdm09 (-2 to 9 DFSO) (*25*) (Methods). The
77 systematic search (Tables S1 to S5) identified 4,274 results. After screening and full-text review,
78 63 studies met the inclusion criteria and contributed to the systematic dataset (Fig. 1) (N = 9,616
79 total specimens), which included adult (N = 5,030) and pediatric (N = 1,594) cases from 15
80 countries and specimen measurements for asymptomatic (N = 2,387), presymptomatic (N = 28)
81 and symptomatic (N = 7,146) infections. According to a hybrid Joanna Briggs Institute critical
82 appraisal checklist, risk of bias was low for most contributing studies (Table S6).

83

84 **Association of overdispersion with heterogeneity in rVL**

85 We hypothesized that individual case variation in rVL facilitates the distinctions in *k* among
86 COVID-19, SARS and A(H1N1)pdm09. For each study in the systematic dataset, we used
87 specimen measurements (viral RNA concentration in a respiratory specimen) to estimate rVLs
88 (viral RNA concentration in the respiratory tract) (Methods). To investigate the relationship
89 between *k* and heterogeneity in rVL, we performed a meta-regression using each contributing
90 study (fig. S1), which showed a weak, negative association between the two variables (meta-
91 regression slope *t*-test: $P = 0.040$, Pearson's $r = -0.26$).

92 Using contributing studies with low risk of bias, meta-regression (Fig. 2) showed a
93 strong, negative association between *k* and heterogeneity in rVL (meta-regression slope *t*-test: P
94 $< 10^{-8}$, Pearson's $r = -0.73$). In this case, each unit increase (1 $\log_{10}$ copies/ml) in the SD of rVL
95 decreased log(*k*) by a factor of -1.41 (95% confidence interval [CI]: -1.80 to -1.03), suggesting
96 that broader heterogeneity in rVL facilitates greater overdispersion in the transmissibility of
97 SARS-CoV-2 than of A(H1N1)pmd09. To investigate mechanistic aspects of this association, we
98 conducted a series of analyses on rVL and then modelled the influence of heterogeneity in rVL
99 on individual infectiousness.

100

101 **Meta-analysis and subgroup analyses of rVL**

102 We first compared rVLs among the emerging infections. We performed a random-effects meta-
103 analysis (fig. S2), which assessed the expected rVL when encountering a COVID-19, SARS or
104 A(H1N1)pdm09 case during the infectious period. This showed that the expected rVL of SARS-
105 CoV-2 was not different from that of SARS-CoV-1 (one-sided Welch's *t*-test: $P = 0.102$) but

106 lesser than that of A(H1N1)pdm09 ($P = 0.044$). We also performed random-effects subgroup
107 analyses for COVID-19 (Fig. 3), which showed that expected SARS-CoV-2 rVLs were similar
108 between pediatric and adult cases ($P = 0.409$) and comparable between
109 symptomatic/presymptomatic and asymptomatic infections ($P = 0.107$). Since these meta-
110 analyses had significant between-study heterogeneity among the mean estimates (Cochran's Q
111 test: $P < 0.001$ for each meta-analysis), we conducted risk-of-bias sensitivity analyses; meta-
112 analyses of low-risk-of-bias studies continued to show significant heterogeneity (figs. S3 to S7).
113

114 **Distributions of rVL**

115 We next analyzed rVL distributions. For all three viruses, rVLs best conformed to Weibull
116 distributions (fig. S8), and we fitted the entirety of individual sample data for each virus in the
117 systematic dataset (Fig. 4A and fig. S8N). While COVID-19 and SARS cases tended to shed
118 lesser virus than those with A(H1N1)pdm09 (fig. S2), broad heterogeneity in SARS-CoV-2 and
119 SARS-CoV-1 rVLs inverted this relationship for highly infectious individuals (Fig. 4A and fig.
120 S9, A to C). At the 90th case percentile (cp) throughout the infectious period, the estimated rVL
121 was 8.91 (95% CI: 8.83-9.00) $\log_{10}$ copies/ml for SARS-CoV-2, whereas it was 8.62 (8.47-8.76)
122 $\log_{10}$ copies/ml for A(H1N1)pdm09 (Table S7). The standard deviation (SD) of the overall rVL
123 distribution for SARS-CoV-2 was 2.04 $\log_{10}$ copies/ml, while it was 1.45 $\log_{10}$ copies/ml for
124 A(H1N1)pdm09, showing that heterogeneity in rVL was indeed broader for SARS-CoV-2.

125 To assess potential sources of heterogeneity in SARS-CoV-2 rVL, we compared rVL
126 distributions among COVID-19 subgroups. In addition to comparable mean estimates (Fig. 3),
127 adult, pediatric, symptomatic/presymptomatic and asymptomatic COVID-19 cases showed
128 similar rVL distributions (Fig. 4, B and C), with SDs of 2.04, 2.06, 2.01 and 2.02 $\log_{10}$

129 copies/ml, respectively. Thus, age and symptomatology minimally influenced case variation in
130 SARS-CoV-2 rVL during the infectious period.
131
132 **SARS-CoV-2 kinetics during respiratory infection**
133 To analyze the influences of disease course, we delineated individual SARS-CoV-2 rVLs by
134 DFSO and fitted the mean estimates to a mechanistic model for viral kinetics (Fig. 4D,
135 Methods). The outputs indicated that, on average, each productively infected cell in the airway
136 epithelium shed SARS-CoV-2 at 1.83 (95% CI: 0.69-2.97) copies/ml day^{-1} and infected up to
137 9.48 susceptible cells (Table S8). The turnover rate for infected epithelial cells was 0.55 (0.30-
138 0.79) days^{-1}, while the half-life of SARS-CoV-2 in the respiratory tract was 2.65 (1.39-28.2)
139 hours. By extrapolating the model to an initial rVL of 0 $\log_{10}$ copies/ml, the estimated incubation
140 period was 5.09 days, which agrees with epidemiological findings (*10*). Conversely, the expected
141 duration of shedding was 30.4 DFSO. Thus, SARS-CoV-2 rVL increased exponentially after
142 infection, peaked around 1 DFSO along with the proportion of infected epithelial cells (fig. S10)
143 and then diminished exponentially.

144 To evaluate case heterogeneity across the infectious period, we fitted distributions for
145 each DFSO (Fig. 4E), which showed that high SARS-CoV-2 rVLs also increased from the
146 presymptomatic period, peaked at 1 DFSO and then decreased towards the end of the first week
147 of illness. For the 90th cp at 1 DFSO, the rVL was 9.83 (95% CI: 9.12-10.61) $\log_{10}$ copies/ml, an
148 order of magnitude greater than the overall 90th-cp estimate. High rVLs between 1-5 DFSO were
149 elevated above the expected values from the overall rVL distribution (Table S7). At -1 DFSO,
150 the 90th-cp rVL was 8.30 (6.88-10.02) $\log_{10}$ copies/ml, while it was 7.96 (7.37-8.58) $\log_{10}$

151 copies/ml at 10 DFSO. Moreover, heterogeneity in rVL remained broad across the infectious
152 period, with SDs of 1.85-2.46 $\log_{10}$ copies/ml between -1 to 10 DFSO (fig. S9, H to S).
153
154 **Likelihood that droplets and aerosols contain virions**
155 Towards analyzing the influence of heterogeneity in rVL on individual infectiousness, we first
156 modelled the likelihood of respiratory particles containing viable SARS-CoV-2. Since rVL is an
157 intensive quantity, the volume fraction of virions is low and viral partitioning coincides with
158 atomization, we used Poisson statistics to model likelihood profiles. To calculate an unbiased
159 estimator of partitioning (the expected number of viable copies per particle), our method
160 multiplied rVL estimates with particle volumes during atomization and an assumed viability
161 proportion of 0.1% in equilibrated particles (Methods).

162 When expelled by the mean COVID-19 case during the infectious period, respiratory
163 particles showed low likelihoods of carrying viable SARS-CoV-2 (fig. S11B). Aerosols
164 (equilibrium aerodynamic diameter [d_a] ≤ 100 μm) were ≤0.69% (95% CI: 0.43-0.95%) likely to
165 contain a virion. Droplets also had low likelihoods: at d_a = 330 μm, they were 19.4% (18.5-
166 20.3%), 2.42% (2.15-2.69%) and 0.20% (0.16-0.24%) likely to contain one, two or three virions,
167 respectively.

168 COVID-19 cases with high rVLs, however, expelled particles with considerably greater
169 likelihoods of carrying viable copies (Fig. 5, A and B, and fig. S11, D and E). For the 80th cp
170 during the infectious period, aerosols (d_a ≤ 100 μm) were ≤36.6% (95% CI: 35.3-38.0%) likely
171 to carry at least one SARS-CoV-2 virion. For the 90th cp, this likelihood was ≤96.7% (96.5-
172 96.9%), with larger aerosols tending to contain multiple virions (fig. S11E). At 1 DFSO, these
173 estimates were greatest, and ≤65.2% (56.1-74.3%) of buoyant aerosols (d_a ≤ 10 μm) contained at

174 least one viable copy of SARS-CoV-2 for the 98th cp. When expelled by high cps, droplets (d_a >
175 100 μm) tended to contain tens to thousands of SARS-CoV-2 virions (fig. S11E and Fig. 5B)
176
177 **Shedding SARS-CoV-2 via respiratory droplets and aerosols**
178 Using the partitioning estimates in conjunction with published profiles of the particles expelled
179 by respiratory activities (fig. S12), we next modelled the rates at which talking, singing,
180 breathing and coughing shed viable SARS-CoV-2 across d_a (Fig. 5, C to F). Singing shed virions
181 more rapidly than talking based on the increased emission of aerosols. Voice amplitude,
182 however, had a significant effect on aerosol production, and talking loudly emitted aerosols at
183 similar rates to singing (fig. S12E). Based on the generation of larger aerosols and droplets,
184 talking and singing shed virions more rapidly than breathing (Fig. 5, C to E). Each cough shed
185 similar quantities of virions as in a minute of talking (Fig. 5, C and F).
186 Each of these respiratory activities expelled aerosols at greater rates than droplets, but
187 particle size correlated with the likelihood of containing virions. Talking, singing and coughing
188 expelled virions at greater proportions via droplets (80.6-86.0%) than aerosols (14.0-19.4%)
189 (Fig. 5G). Moreover, short-range aerosols predominantly mediated the virions (90.8-92.6%) shed
190 via aerosols while talking normally and coughing. In comparison, while singing, talking loudly
191 and breathing, buoyant (29.7-68.4%) and long-range (10.3-31.6%) aerosols carried a larger
192 proportion of the virions shed via aerosols (Fig. 5G).
193
194 **Influence of heterogeneity in rVL on individual infectiousness**
195 To interpret how heterogeneity in rVL influences individual infectiousness, we modelled total
196 SARS-CoV-2 shedding rates (over all particle sizes) for each respiratory activity (Fig. 5H and

197 fig. S13). Between the 1st and the 99th cps, the estimates for a respiratory activity spanned ≥8.55
198 orders of magnitude on each DFSO; cumulatively from -1 to 10 DFSO, they spanned 11.0 orders
199 of magnitude. Hence, many COVID-19 cases inherently presented minimal transmission risk,
200 whereas highly infectious individuals shed considerable quantities of SARS-CoV-2. For the 98th
201 cp at 1 DFSO, singing expelled 350 (95% CI: 36.2-4,213) virions/min to the ambient
202 environment, talking emitted 328 (33.9-3,945) virions/min, breathing exhaled 1.73 (0.18-20.7)
203 virions/min and coughing discharged 279 (28.8-3,350) virions/cough; these estimates were
204 approximately two orders of magnitude greater than those for the 86th cp. For the 98th cp at -1
205 DFSO, singing shed 14.5 (0.15-4,515) virions/min and breathing exhaled 7.13×10^{-2} (7.20×10^{-4}-
206 22.2) virions/min. The estimates at 9-10 DFSO were similar to these presymptomatic ones (Fig.
207 5H and fig. S13B). As indicated by comparable mean rVLs (Fig. 3) and heterogeneities in rVL
208 (Fig. 4, B and C), adult, pediatric, symptomatic/presymptomatic and asymptomatic COVID-19
209 subgroups presented similar distributions for shedding virions through these activities.

210 We also compared the influence of case variation on individual infectiousness between
211 A(H1N1)pdm09 and COVID-19. Aerosol spread accounted for approximately half of
212 A(H1N1)pdm09 transmission events (*19*), and the 50% human infectious dose for aerosolized
213 influenza A virus is approximately 1-3 virions in the absence of neutralizing antibodies (*26*).
214 Based on the model, 62.9% of A(H1N1)pdm09 cases were infectious (shed ≥1 virion) via
215 aerosols within 24 h of talking loudly or singing (fig. S14A). The estimate was 58.6% within 24
216 h of talking normally and 22.3% within 24 h of breathing. In comparison, 48.0% of COVID-19
217 cases shed ≥1 virion via aerosols in 24 h of talking loudly or singing (fig. S14C). Notably, only
218 61.4% of COVID-19 cases shed ≥1 virion via either droplets or aerosols in 24 h of talking loudly
219 or singing (fig. S14D). While the human infectious dose of SARS-CoV-2 by any exposure route

220 remains unelucidated, it must be at least one viable copy. Thus, at least 38.6% of COVID-19
221 cases were expected to present negligible risk to spread SARS-CoV-2 through either droplets or
222 aerosols in 24 h. The proportion of inherently infectious cases further decreased as the infectious
223 dose increased: 55.8, 42.5 and 25.0% of COVID-19 cases were expected to shed ≥2, ≥10 and
224 ≥100 virions, respectively, in 24 h of talking loudly or singing.

225 While these analyses indicated that a greater proportion of A(H1N1)pdm09 cases were
226 inherently infectious, 18.8% of COVID-19 cases shed virions more rapidly than those infected
227 with A(H1N1)pdm09 (Fig. 4A). At the 98th cp for A(H1N1)pdm09, singing expelled 4.38 (2.85-
228 6.78) virions/min and breathing exhaled 2.15×10^{-2} (1.40×10^{-2}-3.34×10^{-2}) virions/min. Highly
229 infectious COVID-19 cases expelled virions at rates that were up to 1-2 orders of magnitude
230 greater than their A(H1N1)pdm09 counterparts (Fig. 5H and fig. S15).
231

232 **Discussion**

233 This study provided systematic analyses of several factors characterizing SARS-CoV-2
234 transmissibility. First, we found that broader heterogeneity in rVL facilitates greater
235 overdispersion for SARS-CoV-2 than A(H1N1)pdm09. Our results suggest that many COVID-
236 19 cases infect no one (*12-14*) because they inherently present minimal transmission risk via
237 droplets or aerosols, although behavioral and environmental factors can further abate risk.
238 Meanwhile, highly infectious cases can shed tens to thousands of SARS-CoV-2 virions/min. The
239 model estimates, when corrected to copies rather than virions, align with recent clinical findings
240 for exhalation rates of SARS-CoV-2 (*27*). In comparison, a greater proportion of
241 A(H1N1)pdm09 cases are infectious but shed virions at low rates, which concurs with more
242 uniform transmission and few superspreading events observed during the 2009 H1N1 pandemic

243 (*16, 17*). Moreover, our analyses suggest that heterogeneity in rVL may be generally associated
244 with overdispersion for viral respiratory infections. In this case, rVL distribution can serve as an
245 early correlate for transmission patterns, including superspreading, during outbreaks of novel
246 respiratory viruses, providing insight for disease control before large-scale epidemiological
247 studies empirically characterize *k*. When transmission is highly overdispersed, targeted
248 interventions may disproportionately mitigate infection (*20*), with models estimating that
249 focusing half of control efforts on the most infectious 20% of cases outperforms random control
250 policies threefold (*15*).

251 Second, we analyzed SARS-CoV-2 kinetics during respiratory infection. While
252 heterogeneity remains broad throughout the infectious period, rVL tends to peak at 1 DFSO and
253 be elevated for 1-5 DFSO, coinciding with the period of highest attack rates observed among
254 close contacts (*28*). These results indicate that transmission risk tends to be greatest soon after
255 illness rather than in the presymptomatic period, which concurs with large tracing studies (6.4-
256 12.6% of secondary infections from presymptomatic transmission) (*29, 30*) rather than early
257 temporal models (~44%) (*23*). Furthermore, our kinetic analysis suggests that, on average,
258 SARS-CoV-2 reaches diagnostic concentrations 1.58-3.03 days after respiratory infection (-3.51
259 to -2.06 DFSO), assuming assay detection limits of 1-3 $\log_{10}$ copies/ml, respectively, for
260 nasopharyngeal swabs immersed in 1 ml of transport media.

261 Third, we assessed the relative infectiousness of COVID-19 subgroups. As a common
262 symptom of COVID-19 (*31*), coughing sheds considerable numbers of virions via droplets and
263 short-range aerosols. Thus, symptomatic infections tend to be more contagious than
264 asymptomatic ones, providing one reason as to why asymptomatic cases transmit SARS-CoV-2
265 at lower relative rates (*32*), especially in close contact (*33*), despite similar rVLs and increased

266 contact patterns. Accordingly, children (48-54% of symptomatic cases present with cough) (*34,*
267 *35*) tend to be less contagious than adults (68-80%) (*31, 35*) based on tendencies of
268 symptomatology rather than rVL. Conversely, coughing sheds few virions via smaller aerosols.
269 Our analyses suggest that asymptomatic and symptomatic infections present comparable risks for
270 airborne spread, as do adult and pediatric cases. While singing and talking loudly, highly
271 infectious individuals shed tens to hundreds of SARS-CoV-2 virions/min via long-range and
272 buoyant aerosols.

273 Our study has limitations. The systematic search found a limited number of studies
274 reporting quantitative specimen measurements from the presymptomatic period, meaning these
275 estimates may be sensitive to sampling bias. Although additional studies have reported
276 semiquantitative metrics (cycle thresholds), these data were excluded because they cannot be
277 compared on an absolute scale due to batch effects (*36*), limiting use in compound analyses.
278 Furthermore, this study considered population-level estimates of the infectious periods, viability
279 proportions and rate profiles for respiratory particles, which omit individual or environmental
280 variation. Distinctions in phonetic tendencies and, especially for young children, respiratory
281 capacity lead to variation in particle emission rates (*37*). Some patients shed SARS-CoV-2 with
282 diminishing viability soon after symptom onset (*21*), whereas others produce replication-
283 competent virus for weeks (*38*). It remains unclear how case characteristics and environmental
284 factors affect the viability dynamics of SARS-CoV-2.

285 Taken together, our findings provide a potential path forward for disease control. They
286 support aerosol spread as a transmission mode for SARS-CoV-2, including for conditional
287 superspreading by highly infectious cases. However, with short durations of stay in well-
288 ventilated areas, the exposure risk for aerosols, including long-range and buoyant ones, remains

289 correlated with proximity to infectious cases (*2, 4*). Strategies to abate infection should limit
290 crowd numbers and duration of stay while reinforcing distancing, low voice amplitudes and
291 widespread mask usage; well-ventilated settings can be recognized as lower risk venues.
292 Coughing can shed considerable quantities of virions, while rVL tends to peak at 1 DFSO and
293 can be high throughout the infectious period. Thus, immediate, sustained self-isolation upon
294 illness is crucial to curb transmission from symptomatic cases. Collectively, our analyses
295 highlight the role of infections with high rVLs in propelling the COVID-19 pandemic. While
296 diagnosing COVID-19, qRT-PCR can also triage contact tracing, prioritizing these patients: for
297 nasopharyngeal swabs immersed in 1 ml of transport media, ≥7.14 (95% CI: 7.07-7.22) $\log_{10}$
298 copies/ml corresponds to the top 20% of COVID-19 cases. Doing so may identify asymptomatic
299 and presymptomatic infections more efficiently, a key step towards mitigation as the pandemic
300 continues.

References and Notes:

1. E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect. Dis.* **20**, 533-534 (2020).
2. K. A. Prather, L. C. Marr, R. T. Schooley, M. A. McDiarmid, M. E. Wilson, D. K. Milton, Airborne transmission of SARS-CoV-2. *Science* **370**, 303-304 (2020).
3. C. J. Roy, D. K. Milton, Airborne transmission of communicable infection — the elusive pathway. *N. Engl. J. Med.* **350**, 1710-1712 (2004).
4. L. Liu, Y. Li, P. V. Nielsen, J. Wei, R. L. Jensen, Short-range airborne transmission of expiratory droplets between two people. *Indoor Air* **27**, 452-462 (2017).
5. J. J. Wei, Y. G. Li, Enhanced spread of expiratory droplets by turbulence in a cough jet. *Build. Environ.* **93**, 86-96 (2015).
6. D. K. Chu, E. A. Akl, S. Duda, K. Solo, S. Yaacoub, H. J. Schunemann, C.-S. U. R. G. E. s. authors, Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* **395**, 1973-1987 (2020).
7. S. Y. Park, Y. M. Kim, S. Yi, S. Lee, B. J. Na, C. B. Kim, J. I. Kim, H. S. Kim, Y. B. Kim, Y. Park, I. S. Huh, H. K. Kim, H. J. Yoon, H. Jang, K. Kim, Y. Chang, I. Kim, H. Lee, J. Gwack, S. S. Kim, M. Kim, S. Kweon, Y. J. Choe, O. Park, Y. J. Park, E. K. Jeong, Coronavirus disease outbreak in call center, South Korea. *Emerg. Infect. Dis.* **26**, 1666-1670 (2020).
8. J. Y. Lu, J. N. Gu, K. B. Li, C. H. Xu, W. Z. Su, Z. S. Lai, D. Q. Zhou, C. Yu, B. Xu, Z. C. Yang, COVID-19 outbreak associated with air conditioning in restaurant, Guangzhou, China, 2020. *Emerg. Infect. Dis.* **26**, 1628-1631 (2020).
9. L. Hamner, P. Dubbel, I. Capron, A. Ross, A. Jordan, J. Lee, J. Lynn, A. Ball, S. Narwal, S. Russell, D. Patrick, H. Leibrand, High SARS-CoV-2 attack rate following exposure at a choir practice - Skagit County, Washington, March 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 606-610 (2020).
10. Q. Li, X. Guan, P. Wu, X. Wang, L. Zhou, Y. Tong, R. Ren, K. S. M. Leung, E. H. Y. Lau, J. Y. Wong, X. Xing, N. Xiang, Y. Wu, C. Li, Q. Chen, D. Li, T. Liu, J. Zhao, M. Liu, W. Tu, C. Chen, L. Jin, R. Yang, Q. Wang, S. Zhou, R. Wang, H. Liu, Y. Luo, Y. Liu, G. Shao, H. Li, Z. Tao, Y. Yang, Z. Deng, B. Liu, Z. Ma, Y. Zhang, G. Shi, T. T. Y. Lam, J. T. Wu, G. F. Gao, B. J. Cowling, B. Yang, G. M. Leung, Z. Feng, Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N. Engl. J. Med.* **382**, 1199-1207 (2020).
11. X. Hao, S. Cheng, D. Wu, T. Wu, X. Lin, C. Wang, Reconstruction of the full transmission dynamics of COVID-19 in Wuhan. *Nature* **584**, 420-424 (2020).
12. R. Laxminarayan, B. Wahl, S. R. Dudala, K. Gopal, C. Mohan, S. Neelima, K. S. Jawahar Reddy, J. Radhakrishnan, J. A. Lewnard, Epidemiology and transmission dynamics of COVID-19 in two Indian states. *Science*, eabd7672 (2020).
13. A. Endo, S. Abbott, A. J. Kucharski, S. Funk, Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China. *Wellcome Open Research* **5**, (2020).
14. Q. Bi, Y. Wu, S. Mei, C. Ye, X. Zou, Z. Zhang, X. Liu, L. Wei, S. A. Truelove, T. Zhang, W. Gao, C. Cheng, X. Tang, X. Wu, Y. Wu, B. Sun, S. Huang, Y. Sun, J. Zhang, T. Ma, J. Lessler, T. Feng, Epidemiology and transmission of COVID-19 in 391 cases

345 and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *The*
346 *Lancet Infectious Diseases* **20**, 911-919 (2020).
347 15. J. O. Lloyd-Smith, S. J. Schreiber, P. E. Kopp, W. M. Getz, Superspreading and the
348 effect of individual variation on disease emergence. *Nature* **438**, 355-359 (2005).
349 16. M. G. Roberts, H. Nishiura, Early estimation of the reproduction number in the presence
350 of imported cases: pandemic influenza H1N1-2009 in New Zealand. *PLoS One* **6**, e17835
351 (2011).
352 17. J. Brugger, C. L. Althaus, Transmission of and susceptibility to seasonal influenza in
353 Switzerland from 2003 to 2015. *Epidemics* **30**, 100373 (2020).
354 18. I. T. Yu, Y. Li, T. W. Wong, W. Tam, A. T. Chan, J. H. Lee, D. Y. Leung, T. Ho,
355 Evidence of airborne transmission of the severe acute respiratory syndrome virus. *N.*
356 *Engl. J. Med.* **350**, 1731-1739 (2004).
357 19. B. J. Cowling, D. K. M. Ip, V. J. Fang, P. Suntarattiwong, S. J. Olsen, J. Levy, T. M.
358 Uyeki, G. M. Leung, J. S. M. Peiris, T. Chotpitayasunondh, H. Nishiura, J. M.
359 Simmerman, Aerosol transmission is an important mode of influenza A virus spread.
360 *Nature Communications* **4**, 1935 (2013).
361 20. E. C. Lee, N. I. Wada, M. K. Grabowski, E. S. Gurley, J. Lessler, The engines of SARS-
362 CoV-2 spread. *Science* **370**, 406-407 (2020).
363 21. R. Wolfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M. A. Muller, D.
364 Niemeyer, T. C. Jones, P. Vollmar, C. Rothe, M. Hoelscher, T. Bleicker, S. Brunink, J.
365 Schneider, R. Ehmann, K. Zwirglmaier, C. Drosten, C. Wendtner, Virological assessment
366 of hospitalized patients with COVID-2019. *Nature* **581**, 465-469 (2020).
367 22. M. M. Arons, K. M. Hatfield, S. C. Reddy, A. Kimball, A. James, J. R. Jacobs, J. Taylor,
368 K. Spicer, A. C. Bardossy, L. P. Oakley, S. Tanwar, J. W. Dyal, J. Harney, Z. Chisty, J.
369 M. Bell, M. Methner, P. Paul, C. M. Carlson, H. P. McLaughlin, N. Thornburg, S. Tong,
370 A. Tamin, Y. Tao, A. Uehara, J. Harcourt, S. Clark, C. Brostrom-Smith, L. C. Page, M.
371 Kay, J. Lewis, P. Montgomery, N. D. Stone, T. A. Clark, M. A. Honein, J. S. Duchin, J.
372 A. Jernigan, H.-S. Public, C. King, C. C.-I. Team, Presymptomatic SARS-CoV-2
373 infections and transmission in a skilled nursing facility. *N. Engl. J. Med.* **382**, 2081-2090
374 (2020).
375 23. X. He, E. H. Y. Lau, P. Wu, X. Deng, J. Wang, X. Hao, Y. C. Lau, J. Y. Wong, Y. Guan,
376 X. Tan, X. Mo, Y. Chen, B. Liao, W. Chen, F. Hu, Q. Zhang, M. Zhong, Y. Wu, L. Zhao,
377 F. Zhang, B. J. Cowling, F. Li, G. M. Leung, Temporal dynamics in viral shedding and
378 transmissibility of COVID-19. *Nat. Med.* **26**, 672-675 (2020).
379 24. V. E. Pitzer, G. M. Leung, M. Lipsitch, Estimating variability in the transmission of
380 severe acute respiratory syndrome to household contacts in Hong Kong, China. *Am. J.*
381 *Epidemiol.* **166**, 355-363 (2007).
382 25. D. K. Ip, L. L. Lau, N. H. Leung, V. J. Fang, K. H. Chan, D. K. Chu, G. M. Leung, J. S.
383 Peiris, T. M. Uyeki, B. J. Cowling, Viral shedding and transmission potential of
384 asymptomatic and paucisymptomatic influenza virus infections in the community. *Clin.*
385 *Infect. Dis.* **64**, 736-742 (2017).
386 26. P. Fabian, J. J. McDevitt, W. H. DeHaan, R. O. Fung, B. J. Cowling, K. H. Chan, G. M.
387 Leung, D. K. Milton, Influenza virus in human exhaled breath: an observational study.
388 *PLoS One* **3**, e2691 (2008).
389 27. J. Ma, X. Qi, H. Chen, X. Li, Z. Zhang, H. Wang, L. Sun, L. Zhang, J. Guo, L.
390 Morawska, S. A. Grinshpun, P. Biswas, R. C. Flagan, M. Yao, COVID-19 patients in

earlier stages exhaled millions of SARS-CoV-2 per hour. *Clin. Infect. Dis.* 10.1093/cid/ciaa1283 (2020).

28. H. Y. Cheng, S. W. Jian, D. P. Liu, T. C. Ng, W. T. Huang, H. H. Lin, C.-O. I. T. Taiwan, Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. *JAMA Intern Med* **180**, 1156-1163 (2020).
29. W. E. Wei, Z. Li, C. J. Chiew, S. E. Yong, M. P. Toh, V. J. Lee, Presymptomatic transmission of SARS-CoV-2 — Singapore, January 23-March 16, 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 411-415 (2020).
30. Z. Du, X. Xu, Y. Wu, L. Wang, B. J. Cowling, L. A. Meyers, Serial interval of COVID-19 among publicly reported confirmed cases. *Emerg. Infect. Dis.* **26**, 1341-1343 (2020).
31. W. J. Guan, Z. Y. Ni, Y. Hu, W. H. Liang, C. Q. Ou, J. X. He, L. Liu, H. Shan, C. L. Lei, D. S. C. Hui, B. Du, L. J. Li, G. Zeng, K. Y. Yuen, R. C. Chen, C. L. Tang, T. Wang, P. Y. Chen, J. Xiang, S. Y. Li, J. L. Wang, Z. J. Liang, Y. X. Peng, L. Wei, Y. Liu, Y. H. Hu, P. Peng, J. M. Wang, J. Y. Liu, Z. Chen, G. Li, Z. J. Zheng, S. Q. Qiu, J. Luo, C. J. Ye, S. Y. Zhu, N. S. Zhong, C. China Medical Treatment Expert Group for, Clinical characteristics of coronavirus disease 2019 in China. *N. Engl. J. Med.* **382**, 1708-1720 (2020).
32. R. Li, S. Pei, B. Chen, Y. Song, T. Zhang, W. Yang, J. Shaman, Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science* **368**, 489-493 (2020).
33. L. Luo, D. Liu, X. Liao, X. Wu, Q. Jing, J. Zheng, F. Liu, S. Yang, H. Bi, Z. Li, J. Liu, W. Song, W. Zhu, Z. Wang, X. Zhang, Q. Huang, P. Chen, H. Liu, X. Cheng, M. Cai, P. Yang, X. Yang, Z. Han, J. Tang, Y. Ma, C. Mao, Contact settings and risk for transmission in 3410 close contacts of patients with COVID-19 in Guangzhou, China: a prospective cohort study. *Ann. Intern. Med.* 10.7326/M20-2671 (2020).
34. X. Lu, L. Zhang, H. Du, J. Zhang, Y. Y. Li, J. Qu, W. Zhang, Y. Wang, S. Bao, Y. Li, C. Wu, H. Liu, D. Liu, J. Shao, X. Peng, Y. Yang, Z. Liu, Y. Xiang, F. Zhang, R. M. Silva, K. E. Pinkerton, K. Shen, H. Xiao, S. Xu, G. W. K. Wong, T. Chinese Pediatric Novel Coronavirus Study, SARS-CoV-2 infection in children. *N. Engl. J. Med.* **382**, 1663-1665 (2020).
35. C. C.-R. Team, Coronavirus disease 2019 in children - United States, February 12-April 2, 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 422-426 (2020).
36. M. S. Han, J. H. Byun, Y. Cho, J. H. Rim, RT-PCR for SARS-CoV-2: quantitative versus qualitative. *Lancet Infect. Dis.* 10.1016/S1473-3099(20)30424-2 (2020).
37. H.-L. Yen, S. Asadi, A. S. Wexler, C. D. Cappa, S. Barreda, N. M. Bouvier, W. D. Ristenpart, Effect of voicing and articulation manner on aerosol particle emission during human speech. *PLoS One* **15**, e0227699 (2020).
38. J. J. A. van Kampen, D. A. M. C. van de Vijver, P. L. A. Fraaij, B. L. Haagmans, M. M. Lamers, N. Okba, J. P. C. van den Akker, H. Endeman, D. A. M. P. J. Gommers, J. J. Cornelissen, R. A. S. Hoek, M. M. van der Eerden, D. A. Hesselink, H. J. Metselaar, A. Verbon, J. E. M. de Steenwinkel, G. I. Aron, E. C. M. van Gorp, S. van Boheemen, J. C. Voermans, C. A. B. Boucher, R. Molenkamp, M. P. G. Koopmans, C. Geurtsvankessel, A. A. van der Eijk, Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants. medRxiv [preprint] https://doi.org/10.1101/2020.06.08.20125310 (2020).

437 39. D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, P. Group, Preferred reporting items for
438 systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* **6**, e1000097
439 (2009).
440 40. J. P. T. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M. J. Page, V. A. Welch,
441 *Cochrane handbook for systematic reviews of interventions* (John Wiley & Sons,
442 Chichester, UK, 2019).
443 41. Z. Munn, T. H. Barker, S. Moola, C. Tufanaru, C. Stern, A. McArthur, M. Stephenson, E.
444 Aromataris, Methodological quality of case series studies: an introduction to the JBI
445 critical appraisal tool. *JBI Database System Rev Implement Rep* 10.11124/JBISRIR-D-
446 19-00099 (2019).
447 42. S. Moola, Z. Munn, C. Tufanaru, E. Aromataris, K. Sears, R. Sfetcu, M. Currie, K. Lisy,
448 R. Qureshi, P. Mattis, P. Mu, "Chapter 7: systematic reviews of etiology and risk" in
449 *Joanna Briggs Institute Reviewer's Manual.* (The Joanna Briggs Institute, 2020), pp.
450 2019-05.
451 43. Z. Munn, S. Moola, K. Lisy, D. Riitano, C. Tufanaru, Methodological guidance for
452 systematic reviews of observational epidemiological studies reporting prevalence and
453 cumulative incidence data. *Int J Evid Based Healthc* **13**, 147-153 (2015).
454 44. K. M. Johnston, P. Lakzadeh, B. M. K. Donato, S. M. Szabo, Methods of sample size
455 calculation in descriptive retrospective burden of illness studies. *BMC Med. Res.*
456 *Methodol.* **19**, 9 (2019).
457 45. N. Zhang, Y. Gong, F. Meng, Y. Shi, J. Wang, P. Mao, X. Chuai, Y. Bi, P. Yang, F.
458 Wang, Comparative study on virus shedding patterns in nasopharyngeal and fecal
459 specimens of COVID-19 patients. *Sci China Life Sci* 10.1007/s11427-020-1783-9 (2020).
460 46. E. Lavezzo, E. Franchin, C. Ciavarella, G. Cuomo-Dannenburg, L. Barzon, C. Del
461 Vecchio, L. Rossi, R. Manganelli, A. Loregian, N. Navarin, D. Abate, M. Sciro, S.
462 Merigliano, E. De Canale, M. C. Vanuzzo, V. Besutti, F. Saluzzo, F. Onelia, M. Pacenti,
463 S. G. Parisi, G. Carretta, D. Donato, L. Flor, S. Cocchio, G. Masi, A. Sperduti, L.
464 Cattarino, R. Salvador, M. Nicoletti, F. Caldart, G. Castelli, E. Nieddu, B. Labella, L.
465 Fava, M. Drigo, K. A. M. Gaythorpe, C.-R. T. Imperial College, A. R. Brazzale, S.
466 Toppo, M. Trevisan, V. Baldo, C. A. Donnelly, N. M. Ferguson, I. Dorigatti, A. Crisanti,
467 Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature* **584**,
468 425-429 (2020).
469 47. L. Peng, J. Liu, W. Xu, Q. Luo, D. Chen, Z. Lei, Z. Huang, X. Li, K. Deng, B. Lin, Z.
470 Gao, SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs
471 specimens. *J. Med. Virol.*, (2020).
472 48. K. K. To, O. T. Tsang, W. S. Leung, A. R. Tam, T. C. Wu, D. C. Lung, C. C. Yip, J. P.
473 Cai, J. M. Chan, T. S. Chik, D. P. Lau, C. Y. Choi, L. L. Chen, W. M. Chan, K. H. Chan,
474 J. D. Ip, A. C. Ng, R. W. Poon, C. T. Luo, V. C. Cheng, J. F. Chan, I. F. Hung, Z. Chen,
475 H. Chen, K. Y. Yuen, Temporal profiles of viral load in posterior oropharyngeal saliva
476 samples and serum antibody responses during infection by SARS-CoV-2: an
477 observational cohort study. *Lancet Infect. Dis.* **20**, 565-574 (2020).
478 49. L. Zou, F. Ruan, M. Huang, L. Liang, H. Huang, Z. Hong, J. Yu, M. Kang, Y. Song, J.
479 Xia, Q. Guo, T. Song, J. He, H. L. Yen, M. Peiris, J. Wu, SARS-CoV-2 viral load in
480 upper respiratory specimens of infected patients. *N. Engl. J. Med.* **382**, 1177-1179 (2020).
481 50. J. M. Fajnzylber, J. Regan, K. Coxen, H. Corry, C. Wong, A. Rosenthal, D. Worrall, F.
482 Giguel, A. Piechocka-Trocha, C. Atyeo, S. Fischinger, A. Chan, K. T. Flaherty, K. Hall,

483 M. Dougan, E. T. Ryan, E. Gillespie, R. Chishti, Y. Li, N. Jilg, D. Hanidziar, R. M.
484 Baron, L. Baden, A. M. Tsibris, K. A. Armstrong, D. R. Kuritzkes, G. Alter, B. D.
485 Walker, X. Yu, J. Li, SARS-CoV-2 viral load is associated with increased disease
486 severity and mortality. medRxiv [preprint] https://doi.org/10.1101/2020.07.15.20131789
487 (2020)
488 51. S. Zheng, J. Fan, F. Yu, B. Feng, B. Lou, Q. Zou, G. Xie, S. Lin, R. Wang, X. Yang, W.
489 Chen, Q. Wang, D. Zhang, Y. Liu, R. Gong, Z. Ma, S. Lu, Y. Xiao, Y. Gu, J. Zhang, H.
490 Yao, K. Xu, X. Lu, G. Wei, J. Zhou, Q. Fang, H. Cai, Y. Qiu, J. Sheng, Y. Chen, T.
491 Liang, Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in
492 Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ* **369**,
493 m1443 (2020).
494 52. N. J. Lennon, R. P. Bhattacharyya, M. J. Mina, H. L. Rehm, D. T. Hung, S. Smole, A.
495 Woolley, E. S. Lander, S. B. Gabriel, Comparison of viral levels in individuals with or
496 without symptoms at time of COVID-19 testing among 32,480 residents and staff of
497 nursing homes and assisted living facilities in Massachusetts. medRxiv [preprint]
498 https://doi.org/10.1101/2020.07.20.20157792 (2020).
499 53. N. K. Shrestha, F. Marco Canosa, A. S. Nowacki, G. W. Procop, S. Vogel, T. G. Fraser,
500 S. C. Erzurum, P. Terpeluk, S. M. Gordon, Distribution of transmission potential during
501 nonsevere COVID-19 illness. *Clin. Infect. Dis.* 10.1093/cid/ciaa886 (2020).
502 54. F. Shi, T. Wu, X. Zhu, Y. Ge, X. Zeng, Y. Chi, X. Du, L. Zhu, F. Zhu, B. Zhu, L. Cui, B.
503 Wu, Association of viral load with serum biomakers among COVID-19 cases. *Virology*
504 **546**, 122-126 (2020).
505 55. I. F. Hung, K. C. Lung, E. Y. Tso, R. Liu, T. W. Chung, M. Y. Chu, Y. Y. Ng, J. Lo, J.
506 Chan, A. R. Tam, H. P. Shum, V. Chan, A. K. Wu, K. M. Sin, W. S. Leung, W. L. Law,
507 D. C. Lung, S. Sin, P. Yeung, C. C. Yip, R. R. Zhang, A. Y. Fung, E. Y. Yan, K. H.
508 Leung, J. D. Ip, A. W. Chu, W. M. Chan, A. C. Ng, R. Lee, K. Fung, A. Yeung, T. C.
509 Wu, J. W. Chan, W. W. Yan, W. M. Chan, J. F. Chan, A. K. Lie, O. T. Tsang, V. C.
510 Cheng, T. L. Que, C. S. Lau, K. H. Chan, K. K. To, K. Y. Yuen, Triple combination of
511 interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted
512 to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet* **395**, 1695-
513 1704 (2020).
514 56. S. Iwasaki, S. Fujisawa, S. Nakakubo, K. Kamada, Y. Yamashita, T. Fukumoto, K. Sato,
515 S. Oguri, K. Taki, H. Senjo, J. Sugita, K. Hayasaka, S. Konno, M. Nishida, T. Teshima,
516 Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. *J. Infect.* **81**,
517 e145-e147 (2020).
518 57. R. Perera, E. Tso, O. T. Y. Tsang, D. N. C. Tsang, K. Fung, Y. W. Y. Leung, A. W. H.
519 Chin, D. K. W. Chu, S. M. S. Cheng, L. L. M. Poon, V. W. M. Chuang, M. Peiris, SARS-
520 CoV-2 virus culture and subgenomic RNA for respiratory specimens from patients with
521 mild coronavirus disease. *Emerg. Infect. Dis.* **26**, 2701-2704 (2020).
522 58. A. L. Wyllie, J. Fournier, A. Casanovas-Massana, M. Campbell, M. Tokuyama, P.
523 Vijayakumar, J. L. Warren, B. Geng, M. C. Muenker, A. J. Moore, C. B. F. Vogels, M. E.
524 Petrone, I. M. Ott, P. Lu, A. Venkataraman, A. Lu-Culligan, J. Klein, R. Earnest, M.
525 Simonov, R. Datta, R. Handoko, N. Naushad, L. R. Sewanan, J. Valdez, E. B. White, S.
526 Lapidus, C. C. Kalinich, X. Jiang, D. J. Kim, E. Kudo, M. Linehan, T. Mao, M.
527 Moriyama, J. E. Oh, A. Park, J. Silva, E. Song, T. Takahashi, M. Taura, O. E. Weizman,
528 P. Wong, Y. Yang, S. Bermejo, C. D. Odio, S. B. Omer, C. S. Dela Cruz, S. Farhadian,

529 R. A. Martinello, A. Iwasaki, N. D. Grubaugh, A. I. Ko, Saliva or nasopharyngeal swab
530 specimens for detection of SARS-CoV-2. *N. Engl. J. Med.* **383**, 1283-1286 (2020).
531 59. S. Baggio, A. G. L'Huillier, S. Yerly, M. Bellon, N. Wagner, M. Rohr, A. Huttner, G.
532 Blanchard-Rohner, N. Loevy, L. Kaiser, F. Jacquerioz, I. Eckerle, SARS-CoV-2 viral
533 load in the upper respiratory tract of children and adults with early acute COVID-19.
534 *Clin. Infect. Dis.* 10.1093/cid/ciaa1157 (2020).
535 60. C. Lucas, P. Wong, J. Klein, T. B. R. Castro, J. Silva, M. Sundaram, M. K. Ellingson, T.
536 Mao, J. E. Oh, B. Israelow, T. Takahashi, M. Tokuyama, P. Lu, A. Venkataraman, A.
537 Park, S. Mohanty, H. Wang, A. L. Wyllie, C. B. F. Vogels, R. Earnest, S. Lapidus, I. M.
538 Ott, A. J. Moore, M. C. Muenker, J. B. Fournier, M. Campbell, C. D. Odio, A.
539 Casanovas-Massana, I. T. Yale, R. Herbst, A. C. Shaw, R. Medzhitov, W. L. Schulz, N.
540 D. Grubaugh, C. Dela Cruz, S. Farhadian, A. I. Ko, S. B. Omer, A. Iwasaki, Longitudinal
541 analyses reveal immunological misfiring in severe COVID-19. *Nature* **584**, 463-469
542 (2020).
543 61. K. V. Argyropoulos, A. Serrano, J. Hu, M. Black, X. Feng, G. Shen, M. Call, M. J. Kim,
544 A. Lytle, B. Belovarac, T. Vougiouklakis, L. H. Lin, U. Moran, A. Heguy, A. Troxel, M.
545 Snuderl, I. Osman, P. Cotzia, G. Jour, Association of initial viral load in severe acute
546 respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with outcome and
547 symptoms. *Am. J. Pathol.* **190**, 1881-1887 (2020).
548 62. O. Mitja, M. Corbacho-Monne, M. Ubals, C. Tebe, J. Penafiel, A. Tobias, E. Ballana, A.
549 Alemany, N. Riera-Marti, C. A. Perez, C. Suner, P. Laporte, P. Admella, J. Mitja, M.
550 Clua, L. Bertran, M. Sarquella, S. Gavilan, J. Ara, J. M. Argimon, J. Casabona, G.
551 Cuatrecasas, P. Canadas, A. Elizalde-Torrent, R. Fabregat, M. Farre, A. Forcada, G.
552 Flores-Mateo, E. Muntada, N. Nadal, S. Narejos, A. N. Gil-Ortega, N. Prat, J. Puig, C.
553 Quinones, J. Reyes-Urena, F. Ramirez-Viaplana, L. Ruiz, E. Riveira-Munoz, A. Sierra,
554 C. Velasco, R. M. Vivanco-Hidalgo, A. Sentis, G. B. C, B. Clotet, M. Vall-Mayans, B.
555 P.-C.-R. GROUP, Hydroxychloroquine for early treatment of adults with mild Covid-19:
556 a randomized-controlled trial. *Clin. Infect. Dis.* 10.1093/cid/ciaa1009 (2020).
557 63. P. Vetter, C. Eberhardt, B. Meyer, P. Martinez, G. Torriani, F. Pigny, S. Lemeille, S.
558 Cordey, F. Laubscher, D.-L. Vu, A. Calame, M. Schibler, F. Jacquerioz, G. Blanchard,
559 C.-A. Siegrist, L. Kaiser, A. Didierlaurent, i. eckerle, Daily viral kinetics and innate and
560 adaptive immune responses assessment in COVID-19: a case series. medRxiv [preprint]
561 https://doi.org/10.1101/2020.07.02.20143271 (2020).
562 64. Y. Xu, X. Li, B. Zhu, H. Liang, C. Fang, Y. Gong, Q. Guo, X. Sun, D. Zhao, J. Shen, H.
563 Zhang, H. Liu, H. Xia, J. Tang, K. Zhang, S. Gong, Characteristics of pediatric SARS-
564 CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat. Med.* **26**,
565 502-505 (2020).
566 65. J. H. Hurst, S. M. Heston, H. N. Chambers, H. M. Cunningham, M. J. Price, L. Suarez, C.
567 Crew, S. Bose, J. N. Aquino, S. T. Carr, S. M. Griffin, S. H. Smith, K. Jenkins, T. S.
568 Pfeiffer, J. Rodriguez, C. T. Demarco, N. A. De Naeyer, T. C. Gurley, R. Louzao, C. K.
569 Cunningham, W. J. Steinbach, T. N. Denny, D. J. Lugo, M. A. Moody, S. R. Permar, A.
570 T. Rotta, N. A. Turner, E. B. Walter, C. W. Woods, M. S. Kelly, SARS-CoV-2 infections
571 among children in the biospecimens from respiratory virus-exposed kids (BRAVE Kids)
572 Study. medRxiv [preprint] https://doi.org/10.1101/2020.08.18.20166835 (2020).

573 66. A. G. L'Huillier, G. Torriani, F. Pigny, L. Kaiser, I. Eckerle, Culture-competent SARS-
574 CoV-2 in nasopharynx of symptomatic neonates, children, and adolescents. *Emerg.*
575 *Infect. Dis.* **26**, 2494-2497 (2020).
576 67. M. S. Han, M. W. Seong, N. Kim, S. Shin, S. I. Cho, H. Park, T. S. Kim, S. S. Park, E. H.
577 Choi, Viral RNA load in mildly symptomatic and asymptomatic children with COVID-
578 19, Seoul, South Korea. *Emerg. Infect. Dis.* **26**, 2497-2499 (2020).
579 68. Y. Pan, D. Zhang, P. Yang, L. L. M. Poon, Q. Wang, Viral load of SARS-CoV-2 in
580 clinical samples. *Lancet Infect. Dis.* **20**, 411-412 (2020).
581 69. M. S. Han, M. W. Seong, E. Y. Heo, J. H. Park, N. Kim, S. Shin, S. I. Cho, S. S. Park, E.
582 H. Choi, Sequential analysis of viral load in a neonate and her mother infected with
583 SARS-CoV-2. *Clin. Infect. Dis.* 10.1093/cid/ciaa447 (2020).
584 70. H. Kawasuji, Y. Takegoshi, M. Kaneda, A. Ueno, Y. Miyajima, K. Kawago, Y. Fukui, Y.
585 Yoshida, M. Kimura, H. Yamada, I. Sakamaki, H. Tani, Y. Morinaga, Y. Yamamoto,
586 Viral load dynamics in transmissible symptomatic patients with COVID-19. medRxiv
587 [preprint] https://doi.org/10.1101/2020.06.02.20120014 (2020).
588 71. L. L. M. Poon, K. H. Chan, O. K. Wong, W. C. Yam, K. Y. Yuen, Y. Guan, Y. M. D. Lo,
589 J. S. M. Peiris, Early diagnosis of SARS Coronavirus infection by real time RT-PCR. *J.*
590 *Clin. Virol.* **28**, 233-238 (2003).
591 72. W. J. Chen, J. Y. Yang, J. H. Lin, C. S. J. Fann, V. Osyetrov, C. C. King, Y. M. A. Chen,
592 H. L. Chang, H. W. Kuo, F. Liao, M. S. Ho, Nasopharyngeal shedding of severe acute
593 respiratory syndrome-associated coronavirus is associated with genetic polymorphisms.
594 *Clin. Infect. Dis.* **42**, 1561-1569 (2006).
595 73. C. M. Chu, V. C. Cheng, I. F. Hung, M. M. Wong, K. H. Chan, K. S. Chan, R. Y. Kao, L.
596 L. Poon, C. L. Wong, Y. Guan, J. S. Peiris, K. Y. Yuen, H. U. S. S. Group, Role of
597 lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.
598 *Thorax* **59**, 252-256 (2004).
599 74. L. L. Poon, K. H. Chan, O. K. Wong, T. K. Cheung, I. Ng, B. Zheng, W. H. Seto, K. Y.
600 Yuen, Y. Guan, J. S. Peiris, Detection of SARS coronavirus in patients with severe acute
601 respiratory syndrome by conventional and real-time quantitative reverse transcription-
602 PCR assays. *Clin. Chem.* **50**, 67-72 (2004).
603 75. C. M. Chu, V. C. C. Cheng, I. F. N. Hung, K. S. Chan, B. S. F. Tang, T. H. F. Tsang, K.
604 H. Chan, K. Y. Yuen, Viral load distribution in SARS outbreak. *Emerg. Infect. Dis.* **11**,
605 1882-1886 (2005).
606 76. I. F. Hung, V. C. Cheng, A. K. Wu, B. S. Tang, K. H. Chan, C. M. Chu, M. M. Wong, W.
607 T. Hui, L. L. Poon, D. M. Tse, K. S. Chan, P. C. Woo, S. K. Lau, J. S. Peiris, K. Y. Yuen,
608 Viral loads in clinical specimens and SARS manifestations. *Emerg. Infect. Dis.* **10**, 1550-
609 1557 (2004).
610 77. V. C. Cheng, I. F. Hung, B. S. Tang, C. M. Chu, M. M. Wong, K. H. Chan, A. K. Wu, D.
611 M. Tse, K. S. Chan, B. J. Zheng, J. S. Peiris, J. J. Sung, K. Y. Yuen, Viral replication in
612 the nasopharynx is associated with diarrhea in patients with severe acute respiratory
613 syndrome. *Clin. Infect. Dis.* **38**, 467-475 (2004).
614 78. J. S. Peiris, C. M. Chu, V. C. Cheng, K. S. Chan, I. F. Hung, L. L. Poon, K. I. Law, B. S.
615 Tang, T. Y. Hon, C. S. Chan, K. H. Chan, J. S. Ng, B. J. Zheng, W. L. Ng, R. W. Lai, Y.
616 Guan, K. Y. Yuen, H. U. S. S. Group, Clinical progression and viral load in a community
617 outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet* **361**,
618 1767-1772 (2003).

619 79. M. Loeb, P. K. Singh, J. Fox, M. L. Russell, K. Pabbaraju, D. Zarra, S. Wong, B.
620 Neupane, P. Singh, R. Webby, K. Fonseca, Longitudinal study of influenza molecular
621 viral shedding in Hutterite communities. *J. Infect. Dis.* **206**, 1078-1084 (2012).
622 80. T. Suess, U. Buchholz, S. Dupke, R. Grunow, M. an der Heiden, A. Heider, B. Biere, B.
623 Schweiger, W. Haas, G. Krause, G. Robert Koch Institute Shedding Investigation,
624 Shedding and transmission of novel influenza virus A/H1N1 infection in households--
625 Germany, 2009. *Am. J. Epidemiol.* **171**, 1157-1164 (2010).
626 81. C. C. Li, L. Wang, H. L. Eng, H. L. You, L. S. Chang, K. S. Tang, Y. J. Lin, H. C. Kuo,
627 I. K. Lee, J. W. Liu, E. Y. Huang, K. D. Yang, Correlation of pandemic (H1N1) 2009
628 viral load with disease severity and prolonged viral shedding in children. *Emerg. Infect.*
629 *Dis.* **16**, 1265-1272 (2010).
630 82. P. X. Lu, Y. Y. Deng, G. L. Yang, W. L. Liu, Y. X. Liu, H. Huang, Y. X. Wang,
631 Relationship between respiratory viral load and lung lesion severity: a study in 24 cases
632 of pandemic H1N1 2009 influenza A pneumonia. *J. Thorac. Dis.* **4**, 377-383 (2012).
633 83. D. K. M. Ip, L. L. H. Lau, K. H. Chan, V. J. Fang, G. M. Leung, M. J. S. Peiris, B. J.
634 Cowling, The dynamic relationship between clinical symptomatology and viral shedding
635 in naturally acquired seasonal and pandemic influenza virus infections. *Clin. Infect. Dis.*
636 **62**, 431-437 (2016).
637 84. B. Rath, M. von Kleist, F. Tief, K. Karsch, E. Tuerk, S. Muehlhans, F. Louis, H. Skopnik,
638 B. Schweiger, S. Duwe, Virus load kinetics and resistance development during
639 oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and
640 Influenza B viruses. *Pediatr. Infect. Dis. J.* **31**, 899-905 (2012).
641 85. U. I. Wu, J. T. Wang, Y. C. Chen, S. C. Chang, Severity of pandemic H1N1 2009
642 influenza virus infection may not be directly correlated with initial viral load in upper
643 respiratory tract. *Influenza Other Respir Viruses* **6**, 367-373 (2012).
644 86. S. Meschi, M. Selleri, E. Lalle, L. Bordi, M. B. Valli, F. Ferraro, G. Ippolito, N.
645 Petrosillo, F. N. Lauria, M. R. Capobianchi, Duration of viral shedding in hospitalized
646 patients infected with pandemic H1N1. *BMC Infect. Dis.* **11**, 140 (2011).
647 87. J. R. Yang, J. Lo, Y. L. Ho, H. S. Wu, M. T. Liu, Pandemic H1N1 and seasonal H3N2
648 influenza infection in the human population show different distributions of viral loads,
649 which substantially affect the performance of rapid influenza tests. *Virus Res.* **155**, 163-
650 167 (2011).
651 88. C. Launes, J. J. Garcia-Garcia, I. Jordan, L. Selva, J. Rello, C. Munoz-Almagro, Viral
652 load at diagnosis and influenza A H1N1 (2009) disease severity in children. *Influenza*
653 *Other Respi. Viruses* **6**, e89-e92 (2012).
654 89. B. Killingley, J. Greatorex, S. Cauchemez, J. E. Enstone, M. Curran, R. C. Read, W. S.
655 Lim, A. Hayward, K. G. Nicholson, J. S. Nguyen-Van-Tam, Virus shedding and
656 environmental deposition of novel A (H1N1) pandemic influenza virus: interim findings.
657 *Health Technol. Assess.* **14**, 237-354 (2010).
658 90. N. Lee, P. K. Chan, C. K. Wong, K. T. Wong, K. W. Choi, G. M. Joynt, P. Lam, M. C.
659 Chan, B. C. Wong, G. C. Lui, W. W. Sin, R. Y. Wong, W. Y. Lam, A. C. Yeung, T. F.
660 Leung, H. Y. So, A. W. Yu, J. J. Sung, D. S. Hui, Viral clearance and inflammatory
661 response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus
662 pneumonia. *Antivir. Ther.* **16**, 237-247 (2011).
663 91. P. K. Chan, N. Lee, G. M. Joynt, K. W. Choi, J. L. Cheung, A. C. Yeung, P. Lam, R.
664 Wong, B. W. Leung, H. Y. So, W. Y. Lam, D. C. Hui, Clinical and virological course of

665 infection with haemagglutinin D222G mutant strain of 2009 pandemic influenza A
666 (H1N1) virus. *J. Clin. Virol.* **50**, 320-324 (2011).
667 92. I. F. Hung, K. K. To, C. K. Lee, C. K. Lin, J. F. Chan, H. Tse, V. C. Cheng, H. Chen, P.
668 L. Ho, C. W. Tse, T. K. Ng, T. L. Que, K. H. Chan, K. Y. Yuen, Effect of clinical and
669 virological parameters on the level of neutralizing antibody against pandemic influenza A
670 virus H1N1 2009. *Clin. Infect. Dis.* **51**, 274-279 (2010).
671 93. P. Q. Thai, Q. Mai le, M. R. Welkers, K. Hang Nle, T. Thanh le, V. T. Dung, N. T. Yen,
672 T. N. Duong, N. M. Hoa le, D. D. Thoang, H. T. Trang, M. D. de Jong, H. Wertheim, N.
673 T. Hien, P. Horby, A. Fox, Pandemic H1N1 virus transmission and shedding dynamics in
674 index case households of a prospective Vietnamese cohort. *J. Infect.* **68**, 581-590 (2014).
675 94. M. Ito, S. Nukuzuma, M. Sugie, M. Yoshioka, M. Kon-no, H. Yasutake, Y. Umegaki, Y.
676 Ishikawa, T. Yano, T. Ihara, Detection of pandemic influenza A (H1N1) 2009 virus RNA
677 by real-time reverse transcription polymerase chain reaction. *Pediatr. Int.* **54**, 959-962
678 (2012).
679 95. S. Esposito, C. Daleno, F. Baldanti, A. Scala, G. Campanini, F. Taroni, E. Fossali, C.
680 Pelucchi, N. Principi, Viral shedding in children infected by pandemic A/H1N1/2009
681 influenza virus. *Virol J.* **8**, 349 (2011).
682 96. C. K. Lee, H. K. Lee, T. P. Loh, F. Y. Lai, P. A. Tambyah, L. Chiu, E. S. Koay, J. W.
683 Tang, Comparison of pandemic (H1N1) 2009 and seasonal influenza viral loads,
684 Singapore. *Emerg. Infect. Dis.* **17**, 287-291 (2011).
685 97. I. W. Li, I. F. Hung, K. K. To, K. H. Chan, S. S. Wong, J. F. Chan, V. C. Cheng, O. T.
686 Tsang, S. T. Lai, Y. L. Lau, K. Y. Yuen, The natural viral load profile of patients with
687 pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. *Chest* **137**,
688 759-768 (2010).
689 98. B. J. Cowling, K. H. Chan, V. J. Fang, L. L. H. Lau, H. C. So, R. O. P. Fung, E. S. K.
690 Ma, A. S. K. Kwong, C. W. Chan, W. W. S. Tsui, H. Y. Ngai, D. W. S. Chu, P. W. Y.
691 Lee, M. C. Chiu, G. M. Leung, J. S. M. Peiris, Comparative epidemiology of pandemic
692 and seasonal influenza A in households. *N. Engl. J. Med.* **362**, 2175-2184 (2010).
693 99. K. K. To, K. H. Chan, I. W. Li, T. Y. Tsang, H. Tse, J. F. Chan, I. F. Hung, S. T. Lai, C.
694 W. Leung, Y. W. Kwan, Y. L. Lau, T. K. Ng, V. C. Cheng, J. S. Peiris, K. Y. Yuen, Viral
695 load in patients infected with pandemic H1N1 2009 influenza A virus. *J. Med. Virol.* **82**,
696 1-7 (2010).
697 100. V. R. G. Alves, A. H. Perosa, L. K. de Souza Luna, J. S. Cruz, D. D. Conte, N. Bellei,
698 Influenza A(H1N1)pdm09 infection and viral load analysis in patients with different
699 clinical presentations. *Mem. Inst. Oswaldo Cruz* **115**, e200009 (2020).
700 101. P. K. Cheng, K. K. Wong, G. C. Mak, A. H. Wong, A. Y. Ng, S. Y. Chow, R. K. Lam, C.
701 S. Lau, K. C. Ng, W. Lim, Performance of laboratory diagnostics for the detection of
702 influenza A(H1N1)v virus as correlated with the time after symptom onset and viral load.
703 *J. Clin. Virol.* **47**, 182-185 (2010).
704 102. N. Ngaosuwankul, P. Noisumdaeng, P. Komolsiri, P. Pooruk, K. Chokephaibulkit, T.
705 Chotpitayasunondh, C. Sangsajja, C. Chuchottaworn, J. Farrar, P. Puthavathana,
706 Influenza A viral loads in respiratory samples collected from patients infected with
707 pandemic H1N1, seasonal H1N1 and H3N2 viruses. *Virol J.* **7**, 75 (2010).
708 103. K. K. To, I. F. Hung, I. W. Li, K. L. Lee, C. K. Koo, W. W. Yan, R. Liu, K. Y. Ho, K. H.
709 Chu, C. L. Watt, W. K. Luk, K. Y. Lai, F. L. Chow, T. Mok, T. Buckley, J. F. Chan, S. S.
710 Wong, B. Zheng, H. Chen, C. C. Lau, H. Tse, V. C. Cheng, K. H. Chan, K. Y. Yuen,

711 Delayed clearance of viral load and marked cytokine activation in severe cases of
712 pandemic H1N1 2009 influenza virus infection. *Clin. Infect. Dis.* **50**, 850-859 (2010).
713 104. M. B. Duchamp, J. S. Casalegno, Y. Gillet, E. Frobert, E. Bernard, V. Escuret, G.
714 Billaud, M. Valette, E. Javouhey, B. Lina, D. Floret, F. Morfin, Pandemic A(H1N1)2009
715 influenza virus detection by real time RT-PCR: is viral quantification useful? *Clin.*
716 *Microbiol. Infect.* **16**, 317-321 (2010).
717 105. M. Watanabe, S. Nukuzuma, M. Ito, T. Ihara, Viral load and rapid diagnostic test in
718 patients with pandemic H1N1 2009. *Pediatr. Int.* **53**, 1097-1099 (2011).
719 106. P. Warnke, L. Warning, A. Podbielski, Some are more equal - a comparative study on
720 swab uptake and release of bacterial suspensions. *PLoS One* **9**, e102215 (2014).
721 107. D. C. Adam, P. Wu, J. Y. Wong, E. H. Y. Lau, T. K. Tsang, S. Cauchemez, G. M. Leung,
722 B. J. Cowling, Clustering and superspreading potential of SARS-CoV-2 infections in
723 Hong Kong. *Nat. Med.* 10.1038/s41591-020-1092-0 (2020).
724 108. J. Riou, C. L. Althaus, Pattern of early human-to-human transmission of Wuhan 2019
725 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Euro Surveill.* **25**,
726 (2020).
727 109. Y. Zhang, Y. Li, L. Wang, M. Li, X. Zhou, Evaluating transmission heterogeneity and
728 super-spreading event of COVID-19 in a metropolis of China. *Int. J. Environ. Res. Public*
729 *Health* **17**, 3705 (2020).
730 110. A. Tariq, Y. Lee, K. Roosa, S. Blumberg, P. Yan, S. Ma, G. Chowell, Real-time
731 monitoring the transmission potential of COVID-19 in Singapore, March 2020. *BMC*
732 *Med.* **18**, 166 (2020).
733 111. X. Wan, W. Wang, J. Liu, T. Tong, Estimating the sample mean and standard deviation
734 from the sample size, median, range and/or interquartile range. *BMC Med. Res.*
735 *Methodol.* **14**, 135 (2014).
736 112. P. Baccam, C. Beauchemin, C. A. Macken, F. G. Hayden, A. S. Perelson, Kinetics of
737 influenza A virus infection in humans. *J. Virol.* **80**, 7590-7599 (2006).
738 113. H. Ikeda, S. Nakaoka, R. J. de Boer, S. Morita, N. Misawa, Y. Koyanagi, K. Aihara, K.
739 Sato, S. Iwami, Quantifying the effect of Vpu on the promotion of HIV-1 replication in
740 the humanized mouse model. *Retrovirology* **13**, 23 (2016).
741 114. J. Yan, M. Grantham, J. Pantelic, P. J. Bueno de Mesquita, B. Albert, F. Liu, S. Ehrman,
742 D. K. Milton, E. Consortium, Infectious virus in exhaled breath of symptomatic seasonal
743 influenza cases from a college community. *Proc. Natl. Acad. Sci. U. S. A.* **115**, 1081-
744 1086 (2018).
745 115. L. L. Lau, B. J. Cowling, V. J. Fang, K. H. Chan, E. H. Lau, M. Lipsitch, C. K. Cheng, P.
746 M. Houck, T. M. Uyeki, J. S. Peiris, G. M. Leung, Viral shedding and clinical illness in
747 naturally acquired influenza virus infections. *J. Infect. Dis.* **201**, 1509-1516 (2010).
748 116. H. W. Jeong, S. M. Kim, H. S. Kim, Y. I. Kim, J. H. Kim, J. Y. Cho, S. H. Kim, H. Kang,
749 S. G. Kim, S. J. Park, E. H. Kim, Y. K. Choi, Viable SARS-CoV-2 in various specimens
750 from COVID-19 patients. *Clin. Microbiol. Infect.* 10.1016/j.cmi.2020.07.020 (2020).
751 117. G. R. Johnson, L. Morawska, Z. D. Ristovski, M. Hargreaves, K. Mengersen, C. Y. H.
752 Chao, M. P. Wan, Y. Li, X. Xie, D. Katoshevski, S. Corbett, Modality of human expired
753 aerosol size distributions. *J. Aerosol Sci* **42**, 839-851 (2011).
754 118. L. Morawska, G. R. Johnson, Z. D. Ristovski, M. Hargreaves, K. Mengersen, S. Corbett,
755 C. Y. H. Chao, Y. Li, D. Katoshevski, Size distribution and sites of origin of droplets

expelled from the human respiratory tract during expiratory activities. *J. Aerosol Sci* **40**, 256-269 (2009).

119. S. Asadi, A. S. Wexler, C. D. Cappa, S. Barreda, N. M. Bouvier, W. D. Ristenpart, Aerosol emission and superemission during human speech increase with voice loudness. *Sci. Rep.* **9**, 2348 (2019).

Acknowledgments: We thank T. Alba (Toronto) for discussion on statistical methods. We thank J. Jimenez (Colorado) for discussion on the characteristics of aerosols and droplets. We thank E. Lavezzo and A. Chrisanti (Padova) and A. Wyllie and N. Grubaugh (Yale) for responses to data inquiries.

Funding: This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Toronto COVID-19 Action Fund. P.Z.C. was supported by the NSERC Vanier Scholarship (608544). D.N.F. was supported by the Canadian Institutes of Health Research (Canadian COVID-19 Rapid Research Fund, OV4-170360). F.X.G. was supported by the NSERC Senior Industrial Research Chair.

Author contributions: Conceptualization, P.Z.C.; Methodology, P.Z.C., N.B., and Z.P.; Formal Analysis, P.Z.C.; Investigation, P.Z.C. and N.B.; Resources, Z.P.; Writing – Original Draft, P.Z.C.; Writing – Review & Editing, P.Z.C., N.B., Z.P., M.K., D.N.F., and F.X.G.; Visualization, P.Z.C.; Supervision, M.K., D.N.F., and F.X.G; Funding Acquisition, F.X.G.

Data and materials availability: The systematic dataset and model outputs from this study are uploaded to Zenodo (https://zenodo.org/record/4266560). The code generated during this study is available at GitHub (https://github.com/paulzchen/sars2-heterogeneity). Search strategies for the systematic review are shown in Tables S1 to S5. The systematic review protocol was prospectively registered on PROSPERO (registration number, CRD42020204637).

Competing interests: The authors declare no competing interests.



Fig. 1. Development of the systematic dataset.



Fig. 2. Association of overdispersion in SARS-CoV-2, SARS-CoV-1 and A(H1N1)pdm09 transmissibility with heterogeneity in rVL. Meta-regression of dispersion parameter (k) with the standard deviation (SD) of respiratory viral loads (rVLs) from contributing studies with low risk of bias (Pearson's r = -0.73). Pooled estimates of k were determined from the literature for each infection. Blue, red and yellow circles denote A(H1N1)pdm09 (N = 22), COVID-19 (N = 23) and SARS (N = 7) studies, respectively. Circle sizes denote weighting in the meta-regression. The P-value was obtained using the meta-regression slope t-test.

Subgroup, study ref.	Cases No.	Cases Type	Specimens No.	Specimens DFSO	Specimens Type	Respiratory viral load, log_{10} copies/ml (95% CI)	*P* value for difference
Adult COVID-19							
45	4	H, A, S	9	4 to 10	NPS, OPS	4.12 (3.18-5.05)	
46	100	H, C, A, S, Ps, As	106	-2 to 10	NPS, OPS	4.65 (4.35-4.95)	
47	6	H, A, S	6	3 to 8	OPS	5.13 (4.83-5.42)	
48	23	H, A, S	51	0 to 10	ETA, POS	5.29 (4.65-5.93)	
49	14	H, A, S, As	55	0 to 10	NPS, OPS	5.30 (4.87-5.74)	
50	-	H, N, A, S	31	2 to 10	NPS, OPS, Spu	5.41 (4.81-6.01)	
51	-	H, A, S	19	1 to 10	POS, Spu	5.62 (5.22-6.03)	
52	2,182	C, A, As	2,182	0	NPS	6.01 (5.93-6.09)	
53	171	N, A, S	171	0 to 10	NPS	6.07 (5.79-6.34)	
54	103	H, N, A, S	103	0 to 8	NPS, OPS	6.10 (5.98-6.23)	
21	9	H, A, S, As	133	2 to 10	NPS, OPS, Spu	6.21 (5.90-6.52)	
55	41	H, A, S	310	2 to 10	NPS, OPS, POS	6.28 (6.05-6.50)	
56	5	H, A, S	5	7 to 9	NPS	6.38 (5.16-7.60)	
57	-	H, A, S, As	38	0 to 9	NPA, NPS, OPS, Spu	6.52 (5.77-7.27)	
58	39	H, A, S, As	41	0 to 10	NPS	6.71 (6.20-7.23)	
59	347	H, A, S	347	0 to 5	NPS	6.97 (6.77-7.18)	
60	24	H, A, S	33	0 to 10	NPS	7.51 (6.97-8.05)	
61	205	H, N, A, S	205	0 to 10	NPS	7.55 (7.30-7.81)	
38	-	H, A, S	154	0 to 10	NPS, Spu	7.83 (7.58-8.08)	
62	148	N, A, S	296	1 to 8	NPS	8.04 (7.81-8.28)	
63	5	H, A, S	63	0 to 10	NPS, OPS	8.34 (7.95-8.73)	
Overall ($Q_{20} > 100$, $P < 0.001$, $I^2 = 97.7\%$)						6.33 (5.95-6.70)	-
Pediatric COVID-19							
46	2	H, C, P, S	3	8 to 9	NPS, OPS	3.77 (1.74-5.81)	
64	7	H, P, S, Ps, As	14	-1 to 10	NPS	5.69 (5.26-6.12)	
65	54	C, P, S, Ps, As	54	-3 to 10	NPS	5.82 (5.36-6.29)	
59	58	H, P, S	58	0 to 5	NPS	6.97 (6.45-7.49)	
66	23	H, P, S	23	0 to 4	NPS	7.20 (6.23-8.16)	
67	12	H, P, S, As	27	0 to 10	NPS	8.07 (7.47-8.67)	
Overall ($Q_5 = 52.1$, $P = 0.001$, $I^2 = 90.4\%$)						6.45 (5.55-7.34)	0.409
Symptomatic/presymptomatic COVID-19							
45	4	H, A, S	9	4 to 10	NPS, OPS	4.12 (3.18-5.05)	
46	53	H, C, A, P, S, Ps	60	-2 to 10	NPS, OPS	4.43 (4.03-4.84)	
47	6	H, A, S	6	3 to 8	OPS	5.13 (4.83-5.42)	
49	13	H, A, S	51	0 to 10	NPS, OPS	5.25 (4.79-5.71)	
68	77	H, S, Ps	119	-1 to 8	OPS, Spu	5.26 (4.63-5.90)	
48	23	H, A, S	51	0 to 10	ETA, POS	5.29 (4.65-5.93)	
50	-	H, N, A, S	31	2 to 10	NPS, OPS, Spu	5.41 (4.81-6.01)	
51	-	H, A, S	19	1 to 10	POS, Spu	5.62 (5.22-6.03)	
64	6	H, P, S, Ps	13	-1 to 10	NPS	5.77 (5.10-6.53)	
65	81	C, A, P, S, Ps	81	-3 to 10	NPS	5.78 (5.41-6.15)	
21	8	H, A, S	129	2 to 10	NPS, OPS, Spu	5.88 (5.60-6.17)	
53	171	N, A, S	171	0 to 10	NPS	6.07 (5.79-6.34)	
54	103	H, N, A, S	103	0 to 8	NPS, OPS	6.10 (5.98-6.23)	
55	41	H, A, S	310	2 to 10	NPS, OPS, POS	6.28 (6.05-6.50)	
56	5	H, A, S	5	7 to 9	NPS	6.38 (5.16-7.60)	
58	31	H, A, P, S	33	2 to 10	NPS	6.95 (6.37-7.53)	
59	405	H, A, P, S	405	0 to 5	NPS	6.95 (6.78-7.17)	
66	23	H, P, S	23	0 to 4	NPS	7.20 (6.23-8.16)	
60	24	H, A, S	33	0 to 10	NPS	7.51 (6.97-8.05)	
61	205	H, N, A, S	205	0 to 10	NPS	7.55 (7.30-7.81)	
38	-	H, A, S	154	0 to 10	NPS, Spu	7.83 (7.58-8.08)	
69	2	H, A, P, S	8	4 to 10	NPS, OPS, Spu	7.91 (6.69-9.12)	
62	148	N, A, S	296	1 to 8	NPS	8.04 (7.81-8.28)	
67	9	H, P, S	20	0 to 10	NPS	8.10 (7.37-8.33)	
63	5	H, A, S	63	0 to 10	NPS, OPS	8.34 (7.95-8.73)	
Overall ($Q_{24} > 100$, $P < 0.001$, $I^2 = 97.0\%$)						6.38 (5.98-6.77)	-
Asymptomatic COVID-19							
46	49	H, C, A, As	49	0	NPS, OPS	4.89 (4.46-5.33)	
65	52	C, A, P, As	52	0	NPS	5.31 (4.85-5.77)	
58	9	H, A, As	9	0	NPS	5.67 (4.92-6.43)	
52	2,200	C, A, P, As	2,200	0	NPS	6.01 (5.93-6.09)	
67	3	H, P, As	7	0 to 8	NPS	8.01 (6.91-9.11)	
Overall ($Q_4 = 47.1$, $P < 0.001$, $I^2 = 91.5\%$)						5.84 (5.19-6.50)	0.107



792

Fig. 3. Subgroup analyses of SARS-CoV-2 rVL during the infectious period. Random-effects meta-analyses comparing the expected respiratory viral loads (rVLs) of adult (≥18 years old) COVID-19 cases with pediatric (<18 years old) ones (top) and symptomatic/presymptomatic infections with asymptomatic ones (bottom) during the infectious period. Quantitative rVLs refer to virus concentrations in the respiratory tract. Case types: hospitalized (H), not admitted (N), community (C), adult (A), pediatric (P), symptomatic (S), presymptomatic (Ps) and asymptomatic (As). Specimen types: endotracheal aspirate (ETA), nasopharyngeal aspirate (NPA), nasopharyngeal swab (NPS), oropharyngeal swab (OPS), posterior oropharyngeal saliva (POS) and sputum (Spu). Dashes denote case numbers that were not obtained. Box sizes denote weighting in the overall estimates. Between-study heterogeneity was assessed using the *P*-value from Cochran's *Q* test and the I^2 statistic. One-sided Welch's *t*-tests compared expected rVLs between the COVID-19 subgroups (non-significance, $P > 0.05$).



805

806 **Fig. 4. Heterogeneity and kinetics of SARS-CoV-2 rVL.** (**A**) Estimated distribution of
807 respiratory viral load (rVL) for SARS-CoV-2 (N = 3,820 samples from N = 25 studies) and
808 A(H1N1)pdm09 (N = 512 samples from N = 10 studies) throughout the infectious periods. (**B**
809 and **C**) Estimated distribution of SARS-CoV-2 rVL for adult (N = 3,573 samples from N = 19
810 studies) and pediatric (N = 186 samples from N = 8 studies) (B) and asymptomatic (N = 2,221
811 samples from N = 7 studies) and symptomatic/presymptomatic (N = 1,560 samples from N = 21
812 studies) (C) COVID-19 cases. (**D**) SARS-CoV-2 rVLs fitted to a mechanistic model of viral
813 kinetics (black curve, r^2 = 0.88 for mean estimates). Filled circles and bars depict mean estimates
814 and 95% CIs. Open circles show the entirety of individual sample data over days from symptom
815 onset (DFSO) (left to right, N = 3, 15, 48, 59, 70, 73, 83, 92, 105, 133, 123, 128 and 112 samples
816 from N = 20 studies). (**E**) Estimated distributions of SARS-CoV-2 rVL across DFSO. Weibull
817 distributions were fitted on the entirety of individual sample data for the virus (A), subgroup (B

818 and C) or DFSO (E) in the systematic dataset. Arrows denote 90th case percentiles for SARS-

819 CoV-2 rVL distributions (A and E).



Fig. 5. Heterogeneity in shedding SARS-CoV-2 via droplets and aerosols. (**A** and **B**) Estimated likelihood of respiratory particles containing viable SARS-CoV-2 when expelled by the mean (top) or 98th case percentile (cp) (bottom) COVID-19 cases at -1 (A) or 1 (B) days from symptom onset (DFSO). For higher no. of virions, some likelihood curves were omitted to aid

825 visualization. When the likelihood for 0 virions approaches 0%, particles are expected to contain
826 at least one viable copy. (**C** to **F**) Rate that the mean and 98th-cp COVID-19 cases at 1 DFSO
827 shed viable SARS-CoV-2 by talking (C), singing (D), breathing (E) or coughing (F) over particle
828 size. (**G**) Relative contributions of droplets and aerosols to shedding virions for each respiratory
829 activity (left). Relative contribution of buoyant, long-range and short-range aerosols to shedding
830 virions via aerosols for each respiratory activity (right). (**H**) Case heterogeneity in the total
831 shedding rate (over all particle sizes) of virions via singing across the infectious period. Earlier
832 presymptomatic days were excluded based on limited data. Data range between the 1st and 99th
833 cps. Lines and bands represent estimates and 95% CIs, respectively, for estimated likelihoods or
834 Poisson means.